pituitary axis raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-08-21. Anything still debated is marked as such rather than presented as settled.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Amino acid length | 44 residues | Matches the native peptide backbone |
| Molecular weight | Approximately 5135 Da | Calculated from the peptide sequence |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
| Primary studied use | Visceral fat reduction | Investigated in HIV-associated lipodystrophy |
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
High glucose: activates delta and beta cells, inhibits alpha cells. Low glucose: silences delta and beta cells, activates alpha cells. Glucagon: enhances glucose-induced secretion in beta cells. Insulin: indirectly (possibly, via delta cells) attenuates secretion in alpha cells. Somatostatin: inhibits alpha cells and beta cells. Also inhibits the secretion of pancreatic polypeptide. A large number of G protein-coupled receptors (GPCRs) regulate the secretion of insulin, glucagon, and somatostatin from pancreatic islets, and some of these GPCRs are the targets of drugs used to treat type-2 diabetes (ref GLP-1 receptor agonists, DPPIV inhibitors).
== Drugs that bind to prohibitin == Aurilide Fluorizoline Rocaglamide A Prohibitinn in insect Prohibitin (PHB) is a highly conserved eukaryotic protein complex involved in multiple cellular processes. In insects, PHB has been identified as a potential target protein to insecticidal molecules acting as a receptor of PF2 insecticidal lectin in the midgut of Zabrotes subfasciatus larvae (bean pest) and Cry protein of Bacillus thuringiensis in Leptinotarsa decemlineata (Colorado potato beetle).
=== PE Corporation === In 1999, to focus on the new genomics, Perkin-Elmer Corporation was renamed PE Corporation, and sold its old Analytical Instruments division to EG&G, Inc., which also acquired the Perkin-Elmer name. PE Biosystems remained with PE Corp., and became PE Biosystems Group, with 3,500 employees and net revenues of over $1.2 billion. New instruments were developed and sold for forensic human identification, protein identification and characterization, metabolite pathway identification, and lead compound identification from combinatorial libraries. On April 27, 1999, the shareholders of Perkin-Elmer Corporation approved the reorganization of Perkin-Elmer into PE Corporation, a pure-play life science company. Each share of the Perkin-Elmer stock (PKN) was to be exchanged for one share and for +1⁄2 of a share respectively of the two new common share tracking stocks for the two component Life Sciences groups, PE Biosystems Group and Celera Genomics Group. On April 28, 1999, the two replacement tracking stocks for the new PE Corporation were issued to shareholders. Dr. Michael W. Hunkapiller remained as a Senior Vice President of PE Corporation, and as president of PE Biosystems. On May 6, 1999, the recapitalization of the company resulted in issuance of the two new classes of common stock, called PE Corporation-PE Biosystems Group Common Stock and PE Corporation-Celera Genomics Group Common Stock. On that date, trading began in both new stocks on the New York Stock Exchange, to great excitement.
Sources: en.wikipedia.org
1993/2257) Bath Mental Health Care National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/2258) Wiltshire Health Care National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/2259) North Mersey Community National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/2260) Bath and West Community National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/2261) Royal United Hospital, Bath, National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/2262) Weybourne Community National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/2263) King's Lynn and Wisbech Hospitals National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/2264) Hydrocarbon Oil (Amendment) Regulations 1993 (S.I. 1993/2267) Local Government Act 1988 (Defined Activities) (Exemption) (Horsham District Council and Worthing Borough Council) Order 1993 (S.I. 1993/2269) Finance (No. 2) Act 1992 (Commencement No. 6 and Transitional Provisions and Savings) Order 1993 (S.I. 1993/2272) Income Tax (Employments) (Amendment) Regulations 1993 (S.I. 1993/2276) Smoke Control Areas (Exempted Fireplaces) Order 1993 (S.I. 1993/2277) Sea Fish Licensing (Variation) (No. 2) Order 1993 (S.I. 1993/2291) Friendly Societies (Proxy Voting) Regulations 1993 (S.I. 1993/2294) Commissioners for Oaths (Fees) Order 1993 (S.I. 1993/2297) Commissioners for Oaths (Authorised Persons) (Fees) Order 1993 (S.I.
Quercetin has a bitter flavor and is used as a food additive and in dietary supplements. Hinokitiol (ß-thujaplicin) is used in commercial products for skin, hair and oral care, insect repellents and deodorants. It is also used as a food additive, shelf-life extending agent in food packaging, and wood preservative in timber treatment. Polyene antimycotics, such as nystatin, natamycin and amphotericin B, are a subgroup of macrolides and are widely used antifungal and antileishmanial medications. These drugs act as ionophores by binding to ergosterol in the fungal cell membrane and making it leaky and permeable for K+ and Na+ ions, as a result contributing to fungal cell death. Carboxylic ionophores, i.e., monensin, lasalocid, salinomycin, narasin, maduramicin, semduramycin and laidlomycin, are marketed globally and widely used as anticoccidial feed additives to prevent and treat coccidiosis in poultry. Some of these compounds have also been used as growth and production promoters in certain ruminants, such as cattle, and chickens, however this use has been mainly restricted because of safety issues. Zinc ionophores have been shown to inhibit replication of various viruses in vitro, including coxsackievirus, equine arteritis virus, coronavirus, HCV, HSV, HCoV-229E, HIV, mengovirus, MERS-CoV, rhinovirus, SARS-CoV-1, Zika virus.
=== 18th century === In December 1770, Joel Lane successfully petitioned the North Carolina General Assembly to create a new county. On January 5, 1771, the bill creating Wake County was passed in the General Assembly. The county was formed from portions of Cumberland, Orange, and Johnston counties, and was named for Margaret Wake Tryon, the wife of Governor William Tryon. The first county seat was Bloomsbury. New Bern, a port town on the Neuse River 35 mi (56 km) from the Atlantic Ocean, was the largest city and the capital of North Carolina during the American Revolution. When the British Army laid siege to the city, that site could no longer be used as the capital. From 1789 to 1794, when Raleigh was being built, the state capital was Fayetteville. Raleigh was chosen as the site of the new capital in 1788, as its central location protected it from attacks from the coast. It was officially established in 1792 as both county seat and state capital. The city was incorporated on December 31, 1792, and a charter granted January 21, 1795. The city was named for Sir Walter Raleigh, sponsor of Roanoke, the "lost colony" on Roanoke Island. No known city or town existed previously on the chosen city site. Raleigh is one of the few cities in the United States that was planned and built specifically to serve as a state capital. Its original boundaries were formed by the downtown streets of North, East, West and South. The plan, a grid with two main axes meeting at a central square and an additional square in each corner, was based on Thomas Holme's 1682 plan for Philadelphia.
Sources: en.wikipedia.org
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.
The synthetic peptide incorporates modifications that slow enzymatic breakdown in circulation. Native growth hormone-releasing hormone is short-lived, whereas the analog is designed for greater stability. The core amino acid backbone is largely retained.
The main studied application is reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Research has measured fat changes through imaging. Findings concern fat distribution rather than overall body weight.
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.